REG - Ondine Biomedical - Ondine CEO increases shareholding

Ondine BiomedicalAnnouncement

04/02/2025 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250204:nRSD7578Va&default-theme=true

RNS Number : 7578V  Ondine Biomedical Inc.  04 February 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine CEO increases shareholding in Company as Phase 3 clinical trial
progresses

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, announces that The Pennycook Family
Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn
Cross, has purchased 149,225 shares ("Common Shares") in the Company at a
price of 12.5 pence per Common Share on 03 February 2025.

Following this transaction, Carolyn Cross and Robert Cross, directly and
indirectly, hold  156,314,029 Common Shares representing 35.3621% of the
issued share capital of the Company.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com (http://www.ondinebio.com)
 Carolyn Cross, CEO                                          Via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                            +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         Carolyn Cross and her PCA
 2.      Reason for the Notification
 a)      Position/status                                              Chief Executive Officer (PDMR)
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Ondine Biomedical Inc.
 b)      LEI                                                          9845005B69E07CGF4A56
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Common shares

         Identification code                                          ISIN: CA68234M2058
 b)      Nature of the transaction                                    Share purchase
 c)      Price(s) and volume(s)                                       149,225 shares at 12.5 pence each
 d)      Aggregated information:                                      N/A

         ·Aggregated volume

         ·Price
 e)      Date of the transaction                                      03 February 2025
 f)      Place of the transaction                                     AIM

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHTIMMTMTJMMJA